AARTIPHARM — Aarti Pharmalabs Income Statement
0.000.00%
Last trade - 00:00- IN₹47.26bn
- IN₹48.25bn
- IN₹19.45bn
- 47
- 24
- 72
- 44
Annual income statement for Aarti Pharmalabs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | Interim Report | Interim Report | ARS |
| Standards: | — | — | IAS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 11,999 | 19,452 |
| Cost of Revenue | |||
| Gross Profit | — | 4,748 | 7,755 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 0.046 | 8,793 | 16,653 |
| Operating Profit | -0.046 | 3,206 | 2,799 |
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -0.046 | 1,554 | 2,608 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -0.046 | 1,223 | 1,935 |
| Net Income Before Extraordinary Items | |||
| Net Income | -0.046 | 1,223 | 1,935 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -0.046 | 1,223 | 1,935 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.001 | 27 | 21.4 |
| Dividends per Share |